
{{Act of Congress
| congress       = 113
| session        = 1
| pl             = 1
| title          = 
| override_previous = 
| statvolume     = 
| statpage       = 
| year           = 2013
| month          = 02
| day            = 04
| bill           = 460
| billtype       = hr
| notes          = 
| resolution     = 
| purpose        = To amend title XXVII of the Public Health Service Act to limit co-payment, coinsurance, or other cost-sharing requirements applicable to prescription drugs in a specialty drug tier to the dollar amount (or its equivalent) of such requirements applicable to prescription drugs in a non-preferred brand drug tier, and for other purposes.
}}

{{Center|113th CONGRESS}}


{{Center|1st Session}}


{{Center|H. R. 460}}


{{Center|IN THE HOUSE OF REPRESENTATIVES}}


{{Center|February 4, 2013}}


{{Center|
[[Wikipedia:David McKinley|Mr. McKinley ]](for himself, 
[[Wikipedia:Lois Capps|Mrs. Capps ]], 
[[Wikipedia:Shelley Moore Capito|Mrs. Capito ]], 
[[Wikipedia:Bill Young|Mr. Young of Florida ]], 
[[Wikipedia:Jim Moran|Mr. Moran ]], 
[[Wikipedia:Frank Wolf|Mr. Wolf ]], 
[[Wikipedia:Paul Tonko|Mr. Tonko ]], 
[[Wikipedia:Jon Runyan|Mr. Runyan ]], 
[[Wikipedia:John Conyers|Mr. Conyers ]], 
[[Wikipedia:Suzanne Bonamici|Ms. Bonamici ]], 
[[Wikipedia:David Cicilline|Mr. Cicilline ]], 
[[Wikipedia:Peter DeFazio|Mr. DeFazio ]], 
[[Wikipedia:Mike Michaud|Mr. Michaud ]], 
[[Wikipedia:Sam Farr|Mr. Farr ]], 
[[Wikipedia:Chellie Pingree|Ms. Pingree of Maine ]], 
[[Wikipedia:Charles B. Rangel|Mr. Rangel ]], and 
[[Wikipedia:Ander Crenshaw|Mr. Crenshaw ]]) introduced the following bill; which was referred to the [[Wikipedia:United States House Committee on Energy and Commerce|Committee on Energy and Commerce]]}}


{{Center|A BILL}}

To amend title XXVII of the Public Health Service Act to limit co-payment, coinsurance, or other cost-sharing requirements applicable to prescription drugs in a specialty drug tier to the dollar amount (or its equivalent) of such requirements applicable to prescription drugs in a non-preferred brand drug tier, and for other purposes.
1. Short title


This Act may be cited as the “Patients’ Access to Treatments Act of 2013”.

2. Cost-sharing requirements applicable to prescription drugs in a specialty drug tier


=(a) In general=

Subpart II of part A of title XXVII of the Public Health Service Act ( 42 U.S.C. 300gg et seq. ) is amended by adding at the end the following:

=2719B. Cost-sharing requirements applicable to prescription drugs in a specialty drug tier=


==(a) Requirement==

A group health plan, or a health insurance issuer offering group or individual health insurance, that provides coverage for prescription drugs and uses a formulary or other tiered cost-sharing structure shall not impose cost-sharing requirements applicable to prescription drugs in a specialty drug tier that exceed the dollar amount (or its equivalent) of cost-sharing requirements applicable to prescription drugs in a non-preferred brand drug tier (or prescription drugs in a brand drug tier if there is no non-preferred brand drug tier).
==(b) Special rule==

If a formulary used by a group health plan or a health insurance issuer offering group or individual health insurance contains more than one non-preferred brand drug tier, then the requirements of subsection (a) shall be applied with respect to the non-preferred brand drug tier for which beneficiary cost-sharing is lowest.
==(c) Definitions==

In this section:: The term cost-sharing includes co-payment and coinsurance.: The term drug tier means, with respect to a group health plan or health insurance issuer offering group or individual health insurance coverage that uses a formulary or other cost-sharing structure, a category of drugs—:: within such formulary or structure for which the total dollar amount of cost-sharing requirements for any drug does not vary by more than ten percent from the total dollar amount of cost-sharing requirements for any other drug; and:: that are prescription drugs.: The term non-preferred brand drug tier means, with respect to a group health plan or health insurance issuer offering group or individual health insurance coverage that uses a formulary or other tiered cost-sharing structure, a category of drugs—:: within a drug tier in such formulary or structure for which beneficiary cost-sharing is greater than drug tiers for generic drugs or preferred brand drugs in the formulary or structure;:: that are prescription drugs; and:: that are not included within a specialty drug tier.: The term prescription drug means—:: a drug subject to section 503(b)(1) of the Federal Food, Drug, or Cosmetic Act ; and:: includes a drug described in subparagraph (A) that is a biological product (as defined in section 351(i) of this Act ).: The term specialty drug tier means, with respect to a group health plan or health insurance issuer offering group or individual health insurance coverage that uses a formulary or other tiered cost-sharing structure, a category of drugs—:: within a drug tier in such formulary or structure for which beneficiary cost-sharing is greater than drug tiers for generic drugs, preferred brand drugs, or non-preferred drugs in the plan’s formulary; and:: that are prescription drugs..

=(b) Effective date=

Section 2719B of the Public Health Service Act , as added by subsection (a) , applies to plan years beginning on or after the date of the enactment of this Act.